TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Cutia Therapeutics ( (HK:2487) ) is now available.
Cutia Therapeutics has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has established three committees: the Audit Committee, Remuneration Committee, and Nomination Committee, each with designated members and chairpersons. This announcement reflects the company’s governance structure and may influence its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$9.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands with limited liability, operating in the healthcare industry. It focuses on developing and providing therapeutic solutions, with a market focus that is not explicitly detailed in the release.
Average Trading Volume: 1,252,347
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.14B
For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.